Jumpcode Genomics and Takara Bio USA, Inc. have resolved their patent dispute and joined forces to combine their expertise in CRISPR-based technology for the targeted depletion of undesired transcripts from NGS libraries. The companies have exchanged licenses to utilize each other’s IP, resulting in a collaboration that enhances RNA-seq library sensitivity and reduces sequencing costs by eliminating unwanted abundant sequences. This cutting-edge technology, marketed as DepleteX® and CRISPRclean by Jumpcode, and ZapR technology by Takara Bio USA, holds the potential to revolutionize genomics research by enabling the detection of novel molecules previously undetectable.
The partnership aligns with Jumpcode Genomics’ mission to advance genomics research by removing barriers in critical workflows, allowing for the discovery of previously hidden biological signals. This collaboration leverages the strengths of both companies to provide researchers with innovative tools for breakthrough scientific discoveries. By combining their technologies and expertise, Jumpcode and Takara Bio USA aim to drive the global commercialization of their products, positioning themselves at the forefront of molecular biology innovation.
Through a shared commitment to biotechnology research and development, Takara Bio Inc. and its subsidiary Takara Bio USA are dedicated to enhancing life science research solutions with a range of kits, reagents, and instruments for various applications. The combined IP of the two companies, including patents such as U.S. Patent 11,708,606 and U.S. Patent 10,150,985, underscores their leadership in the field of genome editing and molecular biology. This collaboration not only benefits their customers and partners but also has the potential to advance genomics research and contribute to the detection of pathogens in critical situations, such as future pandemics.
